Life Science News

Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K7A) ("Silo Wellness" or the "Company"), a leading global psychedelics company, is pleased to announce that it has opened its first ecotourism microdosing psilocybin resort and retreat center at Go Natural Jamaica in Long Bay, Portland, Jamaica. "We have been bombarded by cost-conscious client inquiries wanting to explore nature with the help of psilocybin," explained Mike Arnold, an Oregon attorney and the founder of Silo Wellness. "They are what we consider 'psychedelic curious.' These are not looking to experiment with psychedelics for recreational purposes at a club or party. They are very intentional and mindful individuals looking to better understand themselves and their place in the universe. They aren't looking for mental health therapy or a deep dive ego death. They are wanting to learn about psilocybin while learning about themselves. This is an unmet need in the psychedelic space, and Silo Wellness is well positioned to assist.

One of Silo Wellness's most valuable assets is its data. From what the Company has learned from thousands of client inquiries and consumer comments on retreats is that not everyone is looking for the 'deep dive' or to treat mental illnesses. Many want to self-titrate on to mushrooms through serial microdosing. "Our Silonauts often want to be at a rustic seaside resort looking at shooting stars on a gram of mushrooms," stated Arnold. "Or they want to go for a snorkel on a 0.1 gram microdose. They crave an increased connection to nature."

Jamaica Luxury Psychedelic Retreats vs. Psilocybin Microdosing Retreats

Silo's "luxury" retreats have been featured in Bloomberg, Fodor's Travel, The Evening Standard, Men's Health and The Washington Post, among others. However, Silo Wellness never intended to enter the luxury retreats space. "That wasn't my vision," continued Arnold. "Our mission is to put psychedelic healing into the hands of those suffering as quickly and inexpensively as possible. Nonetheless, the luxury model was necessary during COVID and has been very good to us and for our clients. However, it is not available to everyone due to the price point, which is a shame and also contrary to our mission."

"The vision at our Go Natural Jamaica microdosing resort is to offer a lower price point with a seafront 'luxury view' but with more rustic accommodations," Arnold continued. "We can significantly lower the cost by making air conditioning optional, for example, or provide a dorm room with bunk beds right alongside a luxury villa on the same site. I myself prefer to suffer in nature while primitive camping, rafting, or waterfall exploring with or without psychedelics. I don't want to hear the buzz of the A/C at night. I want to hear the buzz of consciousness to the soundtrack of nature. I want to hear a tropical storm. I want to hear the whistling Jamaican tree frogs. I want to sleep under the stars while microdosing. And I want Silo's clients to enjoy this God-given luxury that experienced psychedelic users can do on their own, but in the safety and comfort of secure accommodations under the cover our of risk mitigation protocols."

Spiritual Ecotourism and Psychedelic Retreats in Oregon and Jamaica

Silo Wellness sees nature immersion as essential for human growth. Human consciousness is the most complicated and impressive thing to evolve out of nature - more complicated and inexplicable than a black hole. Silo sees it as incumbent on individuals to explore consciousness while exploring nature to get that reset along with a new purpose-driven download to be the best version of themselves.

In 2022, Silo's Oregon nature-immersion psychedelic retreat was featured in Outside Magazine's article, "The Future of Nature Therapy is Psychedelic." Its colorful narrative begins with an emotional play-by-play account of a ketamine deep-dive trip report by a brave participant with PTSD from sexual assault and depression: "[She] sees the blue pool, shimmering like a winter oasis. It sparkles below a snowy trail and rocky gray cliffs, the iridescent turquoise water rippling under the rushing downpour of Tamolitch Falls…[Her] otherworldly trip didn't happen in the flesh. It took place in her mind, after she'd taken ketamine…"

Beyond what Silo's cliffside beachfront resort has to offer, participants will have optional microdosing nature excursions that can include a waterfall swim, harvesting supper at a permaculture jungle farm, a bamboo raft river float, Caribbean boat tour and island picnic, etc.

Set, Setting, and Dosing: Perceptible Sub-psychedelic Microdosing in Nature

"This retreat isn't necessarily imperceptible microdoses," stated Arnold, "although clients are welcome to experience psychedelics for the first time in this way. Silo's self-titrating psilocybin protocols allow people to work their way up dosing in a controlled way to experience the sub-psychedelic effects.

"We want people to be able to commune with nature at sub-psychedelic but perceptible doses. We know that most of our clients are uncomfortable taking a 0.3 gram 'social dose' or a 0.7 to one gram 'hiker's dose' or 'museum dose' for the first time. Instead, we will provide the framework for them to slowly walk themselves up over time to these more advanced dosages. This prevents the 'cannabis edibles dilemma' of stacking doses with greater than expected effects."

Jamaica Psilocybin Microdosing Retreat Pricing and Shareholder/Owner Discounts

Silo's Labor Day retreat (September 3-6) has lodging and meals starting at $240/night for dorm lodging to $499.99/night for single occupancy with a three-night minimum. Double occupancy is also available. More information can be found at www.SiloWellness.com/jamaica-microdosing.

Farm-/field-/sea-/bush-to-table traditional natural Jamaican cuisine is included. Locally sourced psilocybin mushroom microdosing capsules are available on site for a nominal cash purchase. Applicants receive a one-on-one meeting with our experienced client journey planning team and an evaluation for appropriateness for retreat, contraindications, etc. by our Ph.D. pharmacologist and co-inventor of the world's first psilocybin nasal spray. Qualified participants will also be provided with recommended reading materials, journaling prompts, videos regarding retreat location, logistics, and how to make the most of the process to help them put in the work to reset and reprogram their minds. Additional services can be found on the website, including transportation to retreat, additional add-on lodging before or after retreat, air conditioning, healthful smoothies and natural snacks, yoga, and food upgrade of menu choices (although this is discouraged as we recommend a full emersion into a new lifestyle closer to the land in an authentic local Jamaican fashion).

For a limited time, Silo's shareholders may receive up to 20% off a retreat or priority booking for a private curated retreat for the owner and his or her guests. Owners may also request a special discount code to share on social media for up to 20% off for anyone in their network. Inquire for details and applicability.

Additional Corporate Updates

Since the May 2022 shareholder meeting, the Silo team has been working diligently to secure additional property partnerships in Jamaica to scale up retreats in order to reduce costs and to provide additional revenue through increased inventory. This strategy would provide the opportunity for the Company to negotiate longer-term staffing contracts at a lower price per retreat. In July, the Company successfully conducted a luxury retreat in Trelawny, Jamaica, with positive feedback from participants. The Company has also been working to best position itself for Oregon psilocybin by visiting rural retreat properties for potential purchase or joint venture and intends to purchase an urban retreat center.

The Company's May 2022 letter of intent with Dyscovry Science is still active and that transaction is still expected to close with documents being finalized by the respective attorneys. Additionally, following the 20-1 share consolidation that occurred at the May shareholders meeting, the Company has seen its total shares issued increase due to debt conversions from the first two funding tranches received from the financing announced in April. The Company is in active discussions with other potential finance groups regarding debt restructuring and a potential private placement which would be contingent on renegotiating the April debt financing terms. The company has retained three f The Company may also spinout retreat assets into a separate wholly-owned subsidiary for an Oregon-specific capital raise. Use of proceeds for that would be include closing on a psilocybin service center property, BM 109 licenses fees and expenses, property improvements necessary for licensing, legal fees, marketing, and other administrative and operations costs.

Additionally, the Company entered into an advertising and investor awareness campaign with Dig Media Inc. dba Investing News Network (INN). INN is a private company headquartered in Vancouver, Canada, dedicated to providing independent news and education to investors since 2007 at www.investingnews.com. Beginning today for a 12-month term of the agreement, INN will provide advertising on its website to increase awareness of the issuer. INN does not provide

Investor Relations or Market Making services. The cost of the campaign is $9,165/month. INN can be reached at 604-688-8231 or info@investingnews.com. One purpose of the campaign is to drive awareness to the Company's psychedelic vacations that are offered at a discount to shareholders/owners. Given the activist nature of plant medicine consumers, the Company's goal is to one day have all participants at retreats being shareholders. More information regarding investor discounts can be found at https://www.silowellness.com/benefits/.

ABOUT Silo Wellness

Silo Wellness is a growth-oriented holding company focused on functional mushroom and psychedelic opportunities that benefit from a unified ecosystem and exceptional leadership. Founded in 2018 and headquartered in Toronto, Silo Wellness has a presence in both Jamaica and Oregon. Silo Wellness is a publicly traded company on the Canadian (CSE: SILO) and Frankfurt (FSE: 3K7A) exchanges and trading on the OTCQB Venture Market (OTCQB: SILFF).

For more information about Silo Wellness or to book a Jamaican psilocybin retreat, please visit www.silowellness.com.

Silo Wellness Company Contact:

Mike Arnold, President

541-900-5871

IR at Silo Wellness dot com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking information may relate to anticipated events or results including, but not limited to the Company successfully launching Jamaica microdosing operations, possibly retreat spinout, alternative financing and other statements made in the Corporate Update, and the Company's future business plans. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, regulatory, political and social uncertainties and the potential impact of COVID-19. Such risks and uncertainties include, among others, the risk factors included in Silo Wellness's continuous disclosure documents available on www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Silo Wellness assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/134375

News Provided by Newsfile via QuoteMedia

SILO:CNX
Silo Wellness

Silo Wellness


Keep reading...Show less
Silo Wellness Executes Definitive Agreement to Acquire Dyscovry Science and Its Psilocybin Pharmaceutical Biosynthesis and Research Portfolio

Silo Wellness Executes Definitive Agreement to Acquire Dyscovry Science and Its Psilocybin Pharmaceutical Biosynthesis and Research Portfolio

Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K7A) ("Silo Wellness" or the "Company"), a leading global psychedelics company, and Dyscovry Science Ltd. ("Dyscovry"), a Toronto-based biotechnology company focused on biosynthetic manufacturing of psilocybin and its derivatives targeting a physiological condition, irritable bowel syndrome, today announced the companies have entered into a definitive share exchange agreement through which Silo acquires 100% of Dyscovry.

With Dyscovry's research collaboration with Canadian federal government research laboratories, Dyscovry intends to develop a biotechnological process for the production of psilocybin and its potentially novel molecule derivatives. This transaction affirms Silo's commitment to the psychedelic pharmaceutical space and is expected to add pharmaceutical R&D capabilities to Silo's patent-pending metered-dosing formulations for psilocybin, DMT, mescaline, and 5-MeO-DMT, and its psychedelic retreat expertise to help unlock the value of its strategicportfolio.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Silo Wellness Organizes Jamaican Psilocybin Retreat Team and Advocates to Speak to Lane County  Commissioners Regarding BM109 Optout Vote; Lane County Declines to Refer a Psilocybin Ban to Voters

Silo Wellness Organizes Jamaican Psilocybin Retreat Team and Advocates to Speak to Lane County Commissioners Regarding BM109 Optout Vote; Lane County Declines to Refer a Psilocybin Ban to Voters

Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFD) (FSE: 3K70) ("Silo Wellness" or the "Company"), a leading global psychedelics company, is pleased to announce that the Silo Wellness team coordinated the presentations of eight speakers in support of psilocybin use under Ballot Measure 109 in Lane County, Oregon, (Oregon's largest county by population outside the Portland metro area) at Tuesday's public board of commissioners meeting.

"It is important that Silo Wellness help support the education of local governments and law enforcement, as we are the only Oregon-based publicly traded psychedelics company and the only Oregon-based company with experience providing legal psilocybin use [in Jamaica] through our psychedelic wellness retreats," stated Silo Wellness founder, a Lane County, Oregon, resident since 1998. "We want to prevent any misinformation comparing the roll out of this service-based wellness industry to any perceived mishaps from Oregon's experience in the cannabis space, particularly regarding diversion and impact on neighbors." In written testimony provided to the Board, Mr. Arnold explained that currently Silo Wellness is in advanced negotiations with property owners outside of unincorporated Lane County and didn't technically "have a dog in this fight" at this time.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Silo Wellness Requests Oregon Property Owner Expressions of Interest for Collaborating on Psilocybin Licensing; Other Corporate Updates

Silo Wellness Requests Oregon Property Owner Expressions of Interest for Collaborating on Psilocybin Licensing; Other Corporate Updates

Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) ("Silo Wellness" or the "Company"), a leading global psychedelics company, announces a request for expressions of interests from Oregon property owners who may be considering participation in the regulatory regime under Oregon Ballot Measure 109. "With Silo Wellness as the only publicly traded psychedelic company with legal psychedelic retreat experience and a strong connection to Oregon, we believe we are well positioned to collaborate with other Oregonians interested in participating in this burgeoning market," stated Silo Wellness founder and Oregon lawyer Mike Arnold.

"Over the past months we have been touring properties with owners and realtors and have really turned up our search for properties that may be suitable for Oregon psilocybin as we await the final rules from the Oregon Health Authority," Mr. Arnold continued. "However, I also know that there are many property owners who may believe they are sitting on an ideal property for a facility with no interest in selling, but they may not have the legal expertise, network, or capital to make it happen. It is our goal to leverage our platform to help empower Oregonians who may each have a piece of the puzzle - facilitation experience, business experience, property, capital, or a passion for the medicine - and bring them together to help make this industry by Oregonians for Oregonians."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Silo Wellness Issues Shareholder Letter and Announces New Chief Executive Officer

Silo Wellness Issues Shareholder Letter and Announces New Chief Executive Officer

Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) ("Silo Wellness" or the "Company"), a leading global psychedelics company, announced today that Silo Wellness founder and chairman of the board of directors Mike Arnold is assuming the role of the Company's interim chief executive officer to continue to lead the Company through its planned acquisition of Dyscovry Science Ltd. and in its planned Oregon psilocybin business objectives. The Company and former CEO Douglas K. Gordon have agreed to Mr. Gordon stepping down as CEO, but he will remain involved in the business, including pursuit of global distribution opportunities for sales of Marley One. During his tenure at Silo Wellness, Mr. Gordon was responsible for the creation of the Marley One global mushroom brand in collaboration with the family of legendary musician Bob Marley and for launching psychedelic retreats in Oregon and Jamaica, a first for a publicly traded company. He also led the Company through its public listing in March of 2021 and two major financings. The Board would like to thank him for his leadership over the past two years.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Silo Wellness to Create a Psychedelic Pharmaceutical Manufacturing and Research Portfolio with Proposed Acquisition of Dyscovry Science

Silo Wellness to Create a Psychedelic Pharmaceutical Manufacturing and Research Portfolio with Proposed Acquisition of Dyscovry Science

Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) ("Silo Wellness" or the "Company"), a leading global psychedelics company, is pleased to announce that it has executed a nonbinding letter of intent to acquire 100% of Dyscovry Science Ltd., a Toronto-based biotechnology company. Dyscovry focuses on biosynthetic manufacturing of psilocybin and its derivatives targeting a physiological condition, irritable bowel syndrome. With Dyscovry's research collaboration with Canadian federal government research laboratories, Dyscovry intends to develop a biotechnological process for the production of psilocybin and its potentially novel molecule derivatives.

"We have been working with Brad Dottin and his team at Dyscovry for almost a year now planning this transaction," commented Mike Arnold, Silo Wellness's president and founder. "We have watched the psychedelic market get pummeled as many have been chasing the 'me too' pharma deals, while we stayed focused on preparing for Oregon adult use with a successful Jamaican retreat model while, in the background, working on this unique opportunity. For the first time under one roof, a publicly traded company will provide psychedelic healing right now through Jamaican psychedelic wellness retreats while at the same time innovating the 'what's next' for psychedelic pharmaceutical healing. As an Oregon attorney who founded Silo Wellness in 2018 with the goal of preparing for psilocybin legalization in Oregon, I wanted to ensure that natural psychedelics were never locked up solely behind a pharmacy window controlled by corporations. Our planned acquisition of Dyscovry shows that traditional medicines can coexist alongside modern scientific innovation."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Lobe Sciences Announces the Appointment of Baxter F. Phillips III to Its Board of Directors

Lobe Sciences Announces the Appointment of Baxter F. Phillips III to Its Board of Directors

lobe sciences ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced that Baxter F. Phillips III has been appointed to the Board of Directors of the Company, effective October 3, 2022. Mr. Phillips has more than 20 years of experience leading multinational corporate strategy and finance in the biotechnology and pharmaceutical industry. As a member of the Company's Board of Directors, Mr. Phillips will also serve as the Chairman of the Audit Committees.

"We are thrilled to welcome Baxter to our Board of Directors," said Philip J. Young, Director and CEO of Lobe. "In addition to his strong financial acumen, Baxter brings to Lobe both a broad, practical experience with a variety of public and private pharmaceutical companies, and an in-depth expertise in manufacturing, licencing and marketing. He is highly respected in his field, and we look forward to working with him in meeting our corporate strategic goals."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Lobe Sciences Announces the Expansion of its Patent Portfolio with International Filings

Lobe Sciences Announces the Expansion of its Patent Portfolio with International Filings

Resignation of Board Chairman, Jonathan Gilbert and Shares for Debt Transactions

lobe sciences ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced that it has expanded its patent portfolio through the filing of international patents in Canada, the United States, Europe and Australia for Methods, Compositions and Devices for Treating Mild Traumatic Brain Injury, Post Traumatic Stress Disorder and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Seelos Therapeutics to Collaborate with the Healey & AMG Center for ALS in an Expanded Access Program Funded by a Grant from the National Institute of Neurological Disorders and Stroke under the Accelerating Access to Critical Therapies for ALS Act

- ACT for ALS Funding is for an Expanded Access Program to Study SLS-005 in Amyotrophic Lateral Sclerosis Patients Who Do Not Qualify for Clinical Trials

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it will collaborate with the Sean M. Healey & AMG Center for ALS in an Expanded Access Program (EAP) that will be fully funded by a grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the ACT for ALS.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Lobe Sciences Announces Incorporation of Australian Subsidiary

Lobe Sciences Announces Incorporation of Australian Subsidiary

 lobe sciences ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has incorporated Lobe Sciences Australia Pty Ltd., a 100% owned Australian subsidiary of the Company, to facilitate the three or more clinical trials in Australia with newly announced partner iNGENū Pty Ltd. The trials aim to evaluate Lobe's proprietary psilocin analogues L-130 or L-131. Australian Federal Government's Research & Development tax incentive program will provide rebates to Lobe for up to 43.5% on eligible expenditures for Research and Development conducted in Australia. The clinical trials are expected to commence in late 2022 or early 2023 pending local Regulatory approval.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Nirvana Life Sciences Inc. Deuterates 7-Hydroxymitragynine to Create D7-h, an Analogue that May Improve Research and Formulations using Kratom Derivatives

Nirvana Life Sciences Inc. Deuterates 7-Hydroxymitragynine to Create D7-h, an Analogue that May Improve Research and Formulations using Kratom Derivatives

Nirvana Life Sciences Inc. (Nirvana or the "Company") (CSE: NIRV) a western Canadian based life sciences company aimed at developing psychedelic therapeutic medicines, including non-addictive chronic pain and relapse preventing products is pleased to report filing of a patent for D7-h.

Nirvana Life Sciences Inc. Logo (CNW Group/Nirvana Life Sciences Inc.)

Nirvana Life Sciences Inc. is pleased to announce it has recently filed a patent for the deuterated form of 7-hydroxymitragynine (D7-h), the active compound in kratom responsible for the opiate like effect the plant produces when ingested. Opioid use disorder and opioid addiction remain at epidemic levels in Canada , the US and worldwide.  In 2021, there were 7560 apparent opioid-related deaths in Canada , which is equivalent to 20 people dying each day, and was greater than the average number of Canadians killed daily in motor vehicle collisions. This number continues to grow, with the PHAC projecting as many as 2400 opioid-related deaths in each quarter of 2022.

The use of Kratom in Southeast Asia has been documented back for at least 150 years and is described both as having a stimulant effect for use in hard day labor when fresh leaves are chewed and an analgesic and relaxing effect if brewed into a tea. In the past decade or more, recognition and the use of kratom has grown in Canada , the United States , and the world at large. Although use has increased, there still remains a lack of research regarding kratom and the various different components within it that are active when taken. One important observation that has been made is that people who take kratom do not see the same respiratory decrease that is often the cause of death and overdose in people who take opiates. This is due to 7-hydroxymitragynine being a partial mu opioid agonist, unlike Fentanyl and oxycodone which are full mu opioid agonists and are known to have depressant effects on respiration.

With so many people affected by opioid use disorder, opioid addiction, and the risk of death from using these substances, research into alternative pain formulations is more than ever necessary. In order to create a medicine that has the potential to truly help people with addictions and those living with chronic pain, it is important to have a deep understanding of how these compounds work in the brain and body. Scientists and doctors have long used deuterated drugs to help track how a drug moves through the brain and body, in order to gain a better understanding of its mechanisms.

A deuterated drug is a small molecule medicinal product in which one or more of the hydrogen atoms contained in the drug molecule have been replaced by its heavier stable isotope deuterium. Because of the kinetic isotope effect, deuterium-containing drugs may have significantly lower rates of metabolism, and hence a longer half-life, as can be seen with Deutetrabenazine, a deuterated version of tetrabenazine, developed by Teva and approved by the FDA in 2017 for the treatment of chorea associated with Huntington's disease. Applications of the deuterium isotope effect have increased over time, and it is now applied extensively in mechanistic research focused on the metabolism of drugs, as well as with many other studies that focus on safety, efficacy, tolerability, bioavailability, and pharmacokinetics (PK).

Nirvana Life Sciences Inc. knows the importance of creating a deuterated form of 7-hydroxymitragynine (D7-h) in order to gain a better understanding of the mechanisms of this compound in the body, including knowledge about safety, bioavailability, efficacy, pharmacokinetics (PK) and more. It is our hope that researchers at Nirvana Life Sciences Inc. and elsewhere will be able to use D7-h to fill the gap in knowledge that exists about kratom, to then create safer and more effective alternatives to opiates for people struggling with addiction and chronic pain.

Robert August , lead chemist and Head of Innovation with Nirvana Life Sciences Inc., stated "With research in chronic pain and addiction, and developing treatments for these, being at the forefront of the mission of Nirvana Life Sciences Inc., we are hopeful to see how this development may change not just science, but the lives of many people." We couldn't agree more and are thrilled to add D7-h to our growing portfolio of novel compounds, formulations and processes focused on chronic pain, addiction and trauma.

Nirvana Life Sciences Inc. has been founded with a simple objective of researching and developing non-addictive pain management and relapse prevention products that can provide healthier outcomes for patients who live with chronic pain and/or have battled with addiction. Nirvana believes that using naturally sourced psychedelics in novel formulations holds the promise of delivering non-addictive solutions that are effective in managing pain and addiction. Nirvana's team, consisting of leading researchers from around the globe, will develop therapies that have the potential of freeing millions from addiction and saving society billions of dollars annually

Forward Looking Statements

This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as "forward-looking statements") within the meaning of Canadian securities laws including, without limitation, statements with respect to the future investments by the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes that the expectations reflected in the forward-looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company's actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.

SOURCE Nirvana Life Sciences Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2022/22/c3080.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada

Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada

Optimi Health Corp . ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and other psychedelic substances, most notably MDMA, is pleased to announce that in conjunction with ATMA Journey Centers ("ATMA"), the companies have confirmed their intent to proceed with a Phase I clinical trial application (CTA) that will document the safety of the Optimi's natural psilocybin biomass and 3,4-methylenedioxy-methamphetamine (MDMA) in healthy patients.

Upon Health Canada approval, it would be the first trial to assess both safety and additional markers, such as the mystical experience questionnaire in healthy subjects that have consumed MDMA.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×